Emerging Cannabis Market Poised to Grow
After November’s US elections, 28 states plus the District of Columbia allowed the usage of medical marijuana even as federal law prohibits it. Since then, there has been a rapid acceptance of cannabis by consumers for both medicinal and recreational purposes and the global legal marijuana market is poised to grow to $140.5 billion in 2020 from $28.8 billion in 2015, according to global marketing firm Technavio. Medicine Man Technologies Inc. (OTC: MDCL), Medical Marijuana Inc., GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Cannabis Sativa Inc. (OTC: CBDS)
Matt Karnes of Greenwave Advisors, a research and financial analysis company of the emerging legalized marijuana industry, is very optimistic about the growth of the cannabidiol market, which is used for medical purposes. “In terms of the cannabidiol market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow cannabidiol only – this is in addition to the 28 states plus District of Columbia that have legalized medical marijuana,” he added.
Provider of consulting services that covers all aspects of cannabis cultivations, Medicine Man Technologies Inc. (OTCQB: MDCL) implements a risk averse growing environment, applying high-tech indoor cannabis cultivation equipment and engages in medical and adult use dispensaries. The company is moving ahead to bring the benefits of mutual experience and technologies to a market engaged by marijuana growers in need of augmented productivity. During the month of August, Medicine Man had acquired Pono Publications Inc. and Success Nutrients Inc. in order to include the Three A Light™ cultivation publication that sold more than 800 copies.
Three A Light™ has made plans to release its ‘Professional Grade’ guide that will be sold to Medicine Man Technologies licensed grade clients, by the end of the year. Recently, Medicine Man has negotiated with Pono Publications and Success Nutrients to enter into an Interim Products and Services Support that would have both business to better engage with one another while the final details of the acquisition are worked out. The Company also announced that they are working on acquiring Capital G (Funk Sack and Odor No), having to build out its brand warehouse concept.
The Company has recently launched a new service called “Cultivation MAX”. Cultivation Max provides cultivation advisory services to current operators who wants to increase their yields through deployment of its collective efficiencies. “We anticipate revenues related to this new deployment to include design fees as well as income derived by formula arising from the anticipated improvement experienced in our client’s cultivation practices. While no specific assurances can be provided, we believe this future income stream may be substantial based upon current performance levels noted in the cannabis cultivation landscape within states allowing for access of such related products,” stated Medicine Man Technologies.
GW Pharmaceuticals (NASDAQ: GWPH) is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company’s primary focus is on disorders of the central nervous system including epilepsy. Their leading cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol, or cannabidiol, which is in development for the treatment of a number of rare childhood-onset epilepsy disorders. Its second cannabinoid medicine is the Sativex®, for the treatment of multiple sclerosis spasticity.
Clinical-stage biopharmaceutical company, Cara Therapeutics Inc. (NASDAQ: CARA) focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. Cara has recently complete the enrollment of 8-week multi-dose phase of adaptive trial of I.V. CR845 in Uremic Pruritus. Uremic pruritus, or more fittingly called the “chronic kidney disease-associated pruritus”, is a chronic itching that occurs in patients with advanced or end-stage renal disease. It is acknowledged to affect roughly 20-50 percent of patients with renal failure and will cause long-term pain and suffering.
Clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is currently in developments of therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol, a non-psychoactive cannabinoid, and tetrahydrocannabinol. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. Zynerba’s cannabidiol gel, ZYN002, is the first and only synthetic cannabidiol formulated as a patent protected permeation-enhanced gel for adult refractory epilepsy patients with focal seizures.
Cannabis Sativa Inc. (OTCQB: CBDS) cultivates and markets natural cannabis products. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. The Company is developing a third strain of cannabis plant named CT22. The Company also conducts its operations through its subsidiary, Wild Earth Naturals Incorporated. Wild Earth is an herbal skin care products formulation and marketing company that plans to target the natural healthcare products market in the United States and abroad. It offers Go Deep, Go Deep EXTRA, Face Garden, Body Garden and Lip Garden.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. “The Latest Buzz in Financial News”